Breast cancer stands as one of the major causes for global elevated death rate. The deregulated Wnt signaling pathway is accountable in innumerable types of cancers, especially in breast cancer. Though enumerable strategies have emerged in the recent past to target the Wnt signaling pathway, regrettably none have succeeded in clearing the clinical trials till now. Antimicrobial Peptides have attracted much of attention as anticancer peptides. Most of these peptides are cationic in nature and hence are attracted towards the cancerous cells which possess negative charge due to the presence of phosphatidylserine on the cell membrane. Hence in this present study we tried to arrest the Wnt signaling pathway by inhibiting the activity of β-catenin protein, the major component which accelerates the rate of Wnt signaling pathway using a novel antimicrobial peptide possessing anticancer property. The anticancer property of the peptide was studied and also by adopting insilico studies we have proved that our peptide is able to target the β-catenin protein specifically and could prove as a potential therapeutic agent against breast cancer after further invitro and in vivo studies.